Affymax ($AFFY) is pocketing a $10 million milestone from Takeda on the news that the FDA has accepted the NDA for the anemia treatment peginesatide, a drug formerly known as Hematide. Earlier today Affymax also noted that the FDA had assigned a March 27 action date for the drug. If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent available for anemia associated with CKD patients on dialysis in the United States. Release | Release